The overlapping mechanisms of AD and T2DM justify why AD must be considered as “type 3 diabetes.” This fresh perspective takes us toward an entirely different approach, which involves targeting insulin signaling, and glucose metabolism as a novel therapeutic strategy for AD. Here, INS is linked to Alzheimer disease.